Staphylococcus aureus Bacteremia Pipeline Insight, 2020

(ALBANY, US) DELVEINSIGHT HAS LAUNCHED A NEW REPORT ON Staphylococcus aureus Bacteremia Pipeline Insight

Staphylococcus aureus Bacteremia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Staphylococcus aureus Bacteremia market. A detailed picture of the Staphylococcus aureus Bacteremia pipeline landscape is provided, which includes the disease overview and Staphylococcus aureus Bacteremia treatment guidelines.

The assessment part of the report embraces in-depth Staphylococcus aureus Bacteremia commercial assessment and clinical assessment of the Staphylococcus aureus Bacteremia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Staphylococcus aureus Bacteremia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Staphylococcus Aureus Bacteremia pipeline
Staphylococcus Aureus Bacteremia pipeline

Click Here For Free Sample Page:- https://www.delveinsight.com/sample-request/staphylococcus-aureus-bacteremia-pipeline-insight

Staphylococcus aureus Bacteremia Pipeline development activities

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Staphylococcus aureus Bacteremia with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Staphylococcus aureus Bacteremia treatment.
  • Staphylococcus aureus Bacteremia key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Staphylococcus aureus Bacteremia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Staphylococcus aureus Bacteremia Analytical Perspective by DelveInsight

  • In-depth Staphylococcus aureus Bacteremia Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Staphylococcus aureus Bacteremia Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

  • The Staphylococcus aureus Bacteremia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Staphylococcus aureus Bacteremia across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Staphylococcus aureus Bacteremia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Staphylococcus aureus Bacteremia research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Staphylococcus aureus Bacteremia.

 

KEY FACT FROM THE REPORT

  • S. aureus bacteremia is estimated with an incidence rate ranging from 20 to 50 cases per 100,000 population per year (Van Hal et al. 2012). Even though overall rates of SAB may have stabilized, the incidence of MRSA
    bacteremia has increased dramatically in recent years in both the US and Europe.
  • In the study of 247 evaluable adult patients with S. aureus bacteremia, the episodes of bacteremia were classified according to acquisition type, in which 23.5% were nosocomial (N-SAB), 58.7% were healthcare-associated (HCA-SAB), and 17.8% were community-acquired (CA-SAB) (Atrouni et al., 2009).
  • According to DelveInsight’s analysis, male gender is consistently associated with increased SAB incidence with male-to-female ratios of ∼1.5. The basis for this increased risk is not understood.

 

MAJOR KEY PLAYERS OF THE REPORT

  • Basilea Pharmaceuticals
  • NovaDigm Co.
  • Intron Biotechnology

 

NAME OF DRUGS COVERED IN THE REPORT

  • Oxacillin
  • Ceftobiprole
  • NDV-3A

 

Table of content

1. Report Introduction

2. Staphylococcus aureus Bacteremia 

2.1. Overview

2.2. History

2.3. Staphylococcus aureus Bacteremia Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Staphylococcus aureus Bacteremia Diagnosis

2.6.1. Diagnostic Guidelines

3. Staphylococcus aureus Bacteremia Current Treatment Patterns

3.1. Staphylococcus aureus Bacteremia Treatment Guidelines

4. Staphylococcus aureus Bacteremia – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Staphylococcus aureus Bacteremia companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Staphylococcus aureus Bacteremia Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Staphylococcus aureus Bacteremia Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Staphylococcus aureus Bacteremia Late Stage Products (Phase-III)

7. Staphylococcus aureus Bacteremia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Staphylococcus aureus Bacteremia Discontinued Products

13. Staphylococcus aureus Bacteremia Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Staphylococcus aureus Bacteremia Key Companies

15. Staphylococcus aureus Bacteremia Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Staphylococcus aureus Bacteremia Unmet Needs

18. Staphylococcus aureus Bacteremia Future Perspectives

19. Staphylococcus aureus Bacteremia Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

22. About Delveinsight

Related Report

ABOUT DELVEINSIGHT 

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

CONTACT US:

Shruti Thakur
[email protected]
+91-9650213330

Related posts